.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Predict branded drug patent expiration
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Farmers Insurance
Chinese Patent Office
Argus Health
Express Scripts
US Army
Cipla
Cantor Fitzgerald
Harvard Business School
Federal Trade Commission

Generated: June 28, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 203341

« Back to Dashboard
NDA 203341 describes BOSULIF, which is a drug marketed by Pf Prism Cv and is included in one NDA. It is available from two suppliers. There are five patents protecting this drug and one Paragraph IV challenge. Additional details are available on the BOSULIF profile page.

The generic ingredient in BOSULIF is bosutinib monohydrate. There are five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the bosutinib monohydrate profile page.

Summary for NDA: 203341

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1

Pharmacology for NDA: 203341

Mechanism of ActionProtein Kinase Inhibitors
P-Glycoprotein Inhibitors

Suppliers and Packaging for NDA: 203341

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
BOSULIF
bosutinib monohydrate
 TABLET;ORAL 203341 NDA Pfizer Laboratories Div Pfizer Inc 0069-0135 0069-0135-01 120 TABLET, FILM COATED in 1 BOTTLE (0069-0135-01)
BOSULIF
bosutinib monohydrate
 TABLET;ORAL 203341 NDA Pfizer Laboratories Div Pfizer Inc 0069-0136 0069-0136-01 30 TABLET, FILM COATED in 1 BOTTLE (0069-0136-01)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 100MG BASE
Approval Date:Sep 4, 2012TE:RLD:Yes
Patent:7,767,678Patent Expiration:Nov 23, 2026Product Flag?YSubstance Flag?YDelist Request?
Patent:7,919,625Patent Expiration:Dec 11, 2025Product Flag?YSubstance Flag?Delist Request?
Patent:RE42376Patent Expiration:Apr 13, 2024Product Flag?Substance Flag?YDelist Request?


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Teva
Baxter
Boehringer Ingelheim
Chinese Patent Office
Cipla
Cerilliant
Argus Health
Daiichi Sankyo
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Related Products from thinkBiotech
Links

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot